Globus Medical Q3 revenue $769M (+23% YoY); raises FY2025 EPS guidance to $3.75-$3.85

GLOBUS MEDICAL INC

2025-Q3 EPS reported $2.90 revenue$2,112,511,000

Net sales $769.0M, +22.9% YoY; base business (ex-Nevro) $669.8M (+7.0%); Nevro contributed $99.3M.
GAAP diluted EPS $0.88, up 134% YoY; non-GAAP diluted EPS $1.18, up 42.6% YoY.
FY2025 revenue guidance raised to $2.86-$2.90B; non-GAAP EPS raised to $3.75-$3.85 (prev $3.00-$3.30).
Record non-GAAP free cash flow of $213.9M in Q3; share repurchases of $40M in Q3, total $255.5M YTD.
Nevro acquisition now expected to be accretive to earnings in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.